Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.20 USD
Change Today +0.01 / 5.26%
Volume 4.0K
BTHE On Other Exchanges
Symbol
Exchange
OTC US
As of 5:20 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

boston therapeutics inc (BTHE) Snapshot

Open
$0.20
Previous Close
$0.19
Day High
$0.20
Day Low
$0.20
52 Week High
12/18/14 - $0.80
52 Week Low
03/6/15 - $0.14
Market Cap
7.7M
Average Volume 10 Days
33.5K
EPS TTM
--
Shares Outstanding
38.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON THERAPEUTICS INC (BTHE)

Related News

No related news articles were found.

boston therapeutics inc (BTHE) Related Businessweek News

No Related Businessweek News Found

boston therapeutics inc (BTHE) Details

Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in veterinary medicine applications. Boston Therapeutics, Inc. was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. The company was founded in 2009 and is headquartered in Manchester, New Hampshire.

7 Employees
Last Reported Date: 03/27/15
Founded in 2009

boston therapeutics inc (BTHE) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $98.4K
Compensation as of Fiscal Year 2014.

boston therapeutics inc (BTHE) Key Developments

Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015

Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 . Venue: Caesars Palace, Las Vegas, Nevada, United States.

Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014

Boston Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and fiscal year ended December 31, 2014. For the quarter, the company reported revenue of $12,871 compared to revenue of $80,438 for the fourth quarter ended December 31, 2013. Net loss was $762,495 or $0.02 per basic and diluted share, compared with a net loss of $2,297,972 or $0.06 per basic and diluted share in the prior year's fourth quarter. Operating loss was $756,854 compared to $2,293,123 a year ago. For the year, the company reported revenue of $199,582 compared to revenue of $323,412 for fiscal 2013. The decrease for fiscal 2014 is primarily due to decreased shipments of SUGARDOWN to the company's one significant customer, APC. Net loss was $4,699,939 or $0.12 per basic and diluted share, compared with a net loss of $4,601,503 or $0.18 per basic and diluted share for fiscal 2014. Operating loss was $4,674,347 compared to $4,580,245 a year ago.

Boston Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Boston Therapeutics, Inc. filed its 10-K on Mar 27, 2015 for the period ending Dec 31, 2014. In this report its auditor, McGladrey LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTHE:US $0.20 USD +0.01

BTHE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTHE.
View Industry Companies
 

Industry Analysis

BTHE

Industry Average

Valuation BTHE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.6x
Price/Book 98.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON THERAPEUTICS INC, please visit www.bostonti.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.